Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q3 2021 13F Holders as of 30 Sep 2021
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 14,710,587
- Share change
- +197,297
- Total reported value
- $252,433,000
- Price per share
- $17.35
- Number of holders
- 30
- Value change
- +$4,174,540
- Number of buys
- 22
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| Abingworth LLP |
3/4/5
13F
|
10%+ Owner · Company |
4.1%
from 13F
|
2,970,156
mixed-class rows
|
$53,284,158 | — | 13 May 2021 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
4%
|
2,914,776
|
$38,650,000 | — | 30 Jun 2021 | |
| FMR LLC |
13F
|
Company |
4.3%
|
3,122,512
|
$38,475,000 | — | 30 Jun 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.4%
|
1,738,693
|
$22,170,000 | — | 30 Jun 2021 | |
| KPCB XVI Associates, LLC |
13F
|
Company |
1.9%
|
1,343,152
|
$16,029,000 | — | 30 Jun 2021 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.6%
|
1,132,671
|
$15,008,000 | — | 30 Jun 2021 | |
| Alphabet Inc. |
13F
|
Company |
1.3%
|
944,791
|
$12,528,000 | — | 30 Jun 2021 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.11%
|
81,452
|
$1,079,000 | — | 30 Jun 2021 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.1%
|
75,638
|
$1,003,000 | — | 30 Jun 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.07%
|
52,268
|
$693,000 | — | 30 Jun 2021 | |
| Monashee Investment Management LLC |
13F
|
Company |
0.06%
|
46,069
|
$611,000 | — | 30 Jun 2021 | |
| CAAS CAPITAL MANAGEMENT LP |
13F
|
Company |
0.03%
|
20,000
|
$265,000 | — | 30 Jun 2021 | |
| Raymond James Financial Services Advisors, Inc. |
13F
|
Company |
0.02%
|
17,828
|
$236,000 | — | 30 Jun 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
16,076
|
$213,000 | — | 30 Jun 2021 | |
| Maven Securities LTD |
13F
|
Company |
0.02%
|
13,000
|
$178,000 | — | 30 Jun 2021 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.02%
|
12,841
|
$170,000 | — | 30 Jun 2021 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.02%
|
11,747
|
$156,000 | — | 30 Jun 2021 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
6,212
|
$82,000 | — | 30 Jun 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,784
|
$24,000 | — | 30 Jun 2021 | |
| UBS Group AG |
13F
|
Company |
0%
|
956
|
$13,000 | — | 30 Jun 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0%
|
593
|
$8,000 | — | 30 Jun 2021 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q3 2021
As of 30 Sep 2021,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,710,587 shares.
The largest 10 holders included
FMR LLC, Abingworth LLP, Sofinnova Investments, Inc., CITADEL ADVISORS LLC, KPCB XVI Associates, LLC, Alphabet Inc., Octagon Capital Advisors LP, BlackRock Inc., VANGUARD GROUP INC, and JPMORGAN CHASE & CO.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2021 vs Q2 2021 Across Filers
Q2 2021 holders
21
Q3 2021 holders
30
Holder diff
9
| Investor | Q2 2021 Shares | Q3 2021 Shares | Share Diff | Share Chg % | Q2 2021 Value $ | Q3 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.